Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Phase II Trial Evaluating Efficacy of Trastuzumab Therapy in HER2 FISH Positive and/or HER2 Mutation Positive, Pretreated, Non-Small Cell Lung Cancer Patients (MO20509)

NCT00758134 is registered in ClinicalTrials.gov with Armando Santoro, MD as lead sponsor.

NCT NCT00758134
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00758134 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Phase II Trial Evaluating Efficacy of Trastuzumab Therapy in HER2 FISH Positive and/or HER2 Mutation Positive, Pretreated, Non-Small Cell Lung Cancer Patients (MO20509)
Lead sponsor
Armando Santoro, MD
Phase
Phase 2
Overall status
Terminated
Start date
July 31, 2008
Completion date
December 31, 2010
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer